Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD

Graft-versus-host Disease (GVHD) Clinical Trial

Official title:
A Randomized, Parallel-Cohort Phase 1 Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute Graft Versus Host Disease

Status Completed

Clinical Trial Summary

To determine if Itacitinib in combination with corticosteroids is safe and tolerable in patients with Grade IIB-IVD acute graft-versus-host disease (GVHD).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02614612
Study type	Interventional
Source	Incyte Corporation
Contact
Status	Completed
Phase	Phase 1
Start date	December 2015
Completion date	August 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03112603` - A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)	Phase 3
Completed	`NCT03139604` - GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease	Phase 3
Completed	`NCT02953678` - A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)	Phase 2
Approved for marketing	`NCT03147742` - An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
Approved for marketing	`NCT05722912` - Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD